Seizure aggravation by ampicillin/sulbactam in an elderly patient with status epilepticus

Kaoru Obata1,2, Masako Kinoshita3, Akiyo Shinde1

  • 1Department of Neurology, Tenri Hospital, Tenri, Nara, Japan.

Abstract

Insights

Ampicillin/sulbactam (ABPC/SBT) may worsen seizures in patients with status epilepticus. This case study found that ABPC/SBT administration increased seizure frequency and duration, highlighting the need for careful monitoring.

Area of Science:

  • Neurology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Status epilepticus (SE) is a neurological emergency often complicated by aspiration pneumonia.
  • Ampicillin/sulbactam (ABPC/SBT), a common antibiotic for aspiration pneumonia, belongs to the β-lactam class, known to potentially exacerbate seizures.
  • The impact of ABPC/SBT on seizure activity in SE patients requires investigation.

Purpose of the Study:

  • To investigate whether ampicillin/sulbactam (ABPC/SBT) administration aggravates seizures in a patient with status epilepticus.
  • To evaluate the utility of electroencephalography (EEG) monitoring in assessing seizure severity and identifying causative factors.

Main Methods:

  • A case report of an 84-year-old male with status epilepticus and aspiration pneumonia.
  • Continuous video EEG monitoring was employed to track seizure activity.
  • Seizure frequency and duration were analyzed in the hours before and after each of the ten ABPC/SBT administrations.

Main Results:

  • Administration of ABPC/SBT led to a significant increase in seizure frequency (3.2 to 7.3 seizures per 2 hours, p=0.047).
  • A trend towards increased seizure duration was observed after ABPC/SBT administration (199s to 406s, p=0.079).
  • EEG trendgraph analysis correlated ABPC/SBT administration with heightened seizure activity.

Conclusions:

  • In this patient with status epilepticus, ampicillin/sulbactam (ABPC/SBT) administration was associated with seizure aggravation.
  • EEG monitoring, particularly with trendgraph analysis, is a valuable tool for evaluating seizure severity and potential exacerbating factors in critically ill patients.

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
239
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
118
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
254
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
179
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
161
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
286